These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35717429)

  • 41. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Bian Y; Jiang H; Ma C; Wang L; Zheng J; Jin G; Lu J
    AJR Am J Roentgenol; 2020 Oct; 215(4):852-863. PubMed ID: 32755201
    [No Abstract]   [Full Text] [Related]  

  • 43. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiomics-Based Texture Analysis of
    Atkinson C; Ganeshan B; Endozo R; Wan S; Aldridge MD; Groves AM; Bomanji JB; Gaze MN
    Front Oncol; 2021; 11():686235. PubMed ID: 34408979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic neuroendocrine tumor: prediction of tumor grades by radiomics models based on ultrasound images.
    Dong Y; Yang DH; Tian XF; Lou WH; Wang HZ; Chen S; Qiu YJ; Wang W; Dietrich CF
    Br J Radiol; 2023 Sep; 96(1149):20220783. PubMed ID: 37393539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer.
    Roll W; Masthoff M; Köhler M; Rahbar K; Stegger L; Ventura D; Morgül H; Trebicka J; Schäfers M; Heindel W; Wildgruber M; Schindler P
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):462-471. PubMed ID: 38416178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
    Rose DB; Nellesen D; Neary MP; Cai B
    J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis.
    Xue B; Wu S; Zhang M; Hong J; Liu B; Xu N; Zeng Q; Tang K; Zheng X
    Abdom Radiol (NY); 2021 Aug; 46(8):3835-3844. PubMed ID: 33728532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative Prediction of G1 and G2/3 Grades in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors Using Multimodality Imaging.
    Liu C; Bian Y; Meng Y; Liu F; Cao K; Zhang H; Fang X; Li J; Yu J; Feng X; Ma C; Lu J; Xu J; Shao C
    Acad Radiol; 2022 Apr; 29(4):e49-e60. PubMed ID: 34175209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study.
    Chen X; Yang Z; Yang J; Liao Y; Pang P; Fan W; Chen X
    Cancer Imaging; 2020 Apr; 20(1):24. PubMed ID: 32248822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
    Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
    Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
    Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
    Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of the World Health Organization Grade of rectal neuroendocrine tumors based on CT histogram analysis.
    Liang P; Xu C; Tan F; Li S; Chen M; Hu D; Kamel I; Duan Y; Li Z
    Cancer Med; 2021 Jan; 10(2):595-604. PubMed ID: 33263225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Xie XJ; Liu SY; Chen JY; Zhao Y; Jiang J; Wu L; Zhang XW; Wu Y; Duan H; He B; Luo H; Han D
    Lung Cancer; 2021 Jul; 157():30-39. PubMed ID: 34052706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?
    Wang X; Zhao X; Li Q; Xia W; Peng Z; Zhang R; Li Q; Jian J; Wang W; Tang Y; Liu S; Gao X
    Eur Radiol; 2019 Nov; 29(11):6049-6058. PubMed ID: 30887209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients.
    Granata V; Fusco R; Costa M; Picone C; Cozzi D; Moroni C; La Casella GV; Montanino A; Monti R; Mazzoni F; Grassi R; Malagnino VG; Cappabianca S; Grassi R; Miele V; Petrillo A
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer.
    Tang TY; Li X; Zhang Q; Guo CX; Zhang XZ; Lao MY; Shen YN; Xiao WB; Ying SH; Sun K; Yu RS; Gao SL; Que RS; Chen W; Huang DB; Pang PP; Bai XL; Liang TB
    J Magn Reson Imaging; 2020 Jul; 52(1):231-245. PubMed ID: 31867839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy.
    Cozzi L; Dinapoli N; Fogliata A; Hsu WC; Reggiori G; Lobefalo F; Kirienko M; Sollini M; Franceschini D; Comito T; Franzese C; Scorsetti M; Wang PM
    BMC Cancer; 2017 Dec; 17(1):829. PubMed ID: 29207975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Pavel ME; Singh S; Strosberg JR; Bubuteishvili-Pacaud L; Degtyarev E; Neary MP; Carnaghi C; Tomasek J; Wolin E; Raderer M; Lahner H; Valle JW; Pommier R; Van Cutsem E; Tesselaar MET; Fave GD; Buzzoni R; Hunger M; Eriksson J; Cella D; Ricci JF; Fazio N; Kulke MH; Yao JC
    Lancet Oncol; 2017 Oct; 18(10):1411-1422. PubMed ID: 28838862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.